 Antineoplastic Agents
"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antitumor Drugs
- Drugs, Antitumor
- Antitumor Agents
- Agents, Antitumor
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 6 | 6 | 12 | | 1981 | 5 | 3 | 8 | | 1982 | 7 | 4 | 11 | | 1983 | 6 | 1 | 7 | | 1984 | 3 | 0 | 3 | | 1985 | 2 | 1 | 3 | | 1986 | 3 | 2 | 5 | | 1987 | 2 | 2 | 4 | | 1988 | 5 | 0 | 5 | | 1989 | 6 | 2 | 8 | | 1990 | 1 | 3 | 4 | | 1991 | 3 | 1 | 4 | | 1992 | 6 | 4 | 10 | | 1993 | 7 | 1 | 8 | | 1994 | 12 | 2 | 14 | | 1995 | 5 | 2 | 7 | | 1996 | 13 | 3 | 16 | | 1997 | 8 | 1 | 9 | | 1998 | 23 | 7 | 30 | | 1999 | 9 | 9 | 18 | | 2000 | 17 | 7 | 24 | | 2001 | 25 | 7 | 32 | | 2002 | 37 | 12 | 49 | | 2003 | 33 | 12 | 45 | | 2004 | 39 | 13 | 52 | | 2005 | 34 | 19 | 53 | | 2006 | 38 | 20 | 58 | | 2007 | 49 | 18 | 67 | | 2008 | 35 | 19 | 54 | | 2009 | 44 | 25 | 69 | | 2010 | 58 | 28 | 86 | | 2011 | 62 | 19 | 81 | | 2012 | 55 | 26 | 81 | | 2013 | 54 | 23 | 77 | | 2014 | 68 | 23 | 91 | | 2015 | 75 | 32 | 107 | | 2016 | 60 | 27 | 87 | | 2017 | 46 | 23 | 69 | | 2018 | 42 | 25 | 67 | | 2019 | 43 | 23 | 66 | | 2020 | 32 | 16 | 48 | | 2021 | 42 | 13 | 55 | | 2022 | 12 | 2 | 14 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Löwenberg B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 09 22; 140(12):1345-1377.
-
Davar D, Zappasodi R, Wang H, Naik GS, Sato T, Bauer T, Bajor D, Rixe O, Newman W, Qi J, Holland A, Wong P, Sifferlen L, Piper D, Sirard CA, Merghoub T, Wolchok JD, Luke JJ. Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022 09 15; 28(18):3990-4002.
-
Howard FM, Pearson AT, Nanda R. Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2022 Aug; 195(1):1-15.
-
Ren P, Tiede C, Fanning SW, Adams T, Speirs V, Nelson ER, Cheng C, Moore TW, Greene GL, Tomlinson D, Selvin PR. Labeling of a mutant estrogen receptor with an Affimer in a breast cancer cell line. Biophys J. 2022 10 04; 121(19):3651-3662.
-
Boni V, Fidler MJ, Arkenau HT, Spira A, Meric-Bernstam F, Uboha N, Sanborn RE, Sweis RF, LoRusso P, Nagasaka M, Garcia-Corbacho J, Jalal S, Harding JJ, Kim SK, Miedema IHC, Vugts DJ, Huisman MC, Zwezerijnen GJC, van Dongen GAMS, Menke van der Houven van Oordt CW, Wang S, Dang T, Zein IA, Vasiljeva O, Lyman SK, Paton V, Hannah A, Liu JF. Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029.
-
Marczyk M, Mrukwa A, Yau C, Wolf D, Chen YY, Balassanian R, Nanda R, Parker BA, Krings G, Sattar H, Zeck JC, Albain KS, Boughey JC, Liu MC, Elias AD, Clark AS, Venters SJ, Shad S, Basu A, Asare SM, Buxton M, Asare AL, Rugo HS, Perlmutter J, DeMichele AM, Yee D, Berry DA, Veer LV, Symmans WF, Esserman L, Pusztai L. Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Ann Oncol. 2022 08; 33(8):814-823.
-
LoRusso P, Ratain MJ, Doi T, Rasco DW, de Jonge MJA, Moreno V, Carneiro BA, Devriese LA, Petrich A, Modi D, Morgan-Lappe S, Nuthalapati S, Motwani M, Dunbar M, Glasgow J, Medeiros BC, Calvo E. Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study. Invest New Drugs. 2022 08; 40(4):762-772.
-
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 05 26; 386(21):1973-1985.
-
Zhang X, Trendowski MR, Wilkinson E, Shahbazi M, Dinh PC, Shuey MM. Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. Cancer Med. 2022 07; 11(14):2801-2816.
-
Le X, Sakai H, Felip E, Veillon R, Garassino MC, Raskin J, Cortot AB, Viteri S, Mazieres J, Smit EF, Thomas M, Iams WT, Cho BC, Kim HR, Yang JC, Chen YM, Patel JD, Bestvina CM, Park K, Griesinger F, Johnson M, Gottfried M, Britschgi C, Heymach J, Sikoglu E, Berghoff K, Schumacher KM, Bruns R, Otto G, Paik PK. Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clin Cancer Res. 2022 03 15; 28(6):1117-1126.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|